Scynexis Acquires PXL-770 for $8M Upfront, Eyes $180M in ADPKD Milestones
Event summary
- Scynexis acquires PXL-770 (now SCY-770), an AMPK activator for ADPKD, from Poxel S.A. for $8M upfront plus up to $180M in milestones.
- Phase 2 proof-of-concept study for SCY-770 in ADPKD patients set to begin Q4 2026, with early efficacy readout expected in H2 2027.
- SCY-770 has Orphan Drug Designation and a favorable safety profile from prior clinical trials.
- Scynexis to host conference call March 31, 2026, to discuss the acquisition and corporate update.
The big picture
Scynexis’ acquisition of SCY-770 expands its focus beyond antifungals into rare diseases, targeting a high-unmet-need market with only one approved therapy. The deal reflects a strategic pivot toward high-value, orphan-drug opportunities, though success hinges on clinical validation and commercial execution in a competitive landscape. The $180M in potential milestones underscores the financial stakes of advancing SCY-770 through development.
What we're watching
- Clinical Execution
- Whether SCY-770 can deliver positive Phase 2 data by H2 2027, validating its differentiated mechanism in ADPKD.
- Commercial Potential
- The pace at which SCY-770 could capture market share in ADPKD, currently dominated by Jynarque with limited patient uptake.
- Pipeline Diversification
- How Scynexis balances development of SCY-770 alongside its antifungal assets, including SCY-247.
Related topics